A triple tumor study of MAGE-A10 SPEAR T-cell therapy in patients with inoperable or metastatic urothelial cancer, melanoma, or squamous cell carcinoma of the head and neck

Trial Profile

A triple tumor study of MAGE-A10 SPEAR T-cell therapy in patients with inoperable or metastatic urothelial cancer, melanoma, or squamous cell carcinoma of the head and neck

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs MAGE A-10 TCR-transduced lymphocytes (Primary)
  • Indications Bladder cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Renal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 18 Oct 2016 According to Adaptimmune Therapeutics media release, MD Anderson Cancer Center being the first site initiated.
    • 18 Oct 2016 Status changed from planning to recruiting, as per Adaptimmune Therapeutics media release.
    • 29 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top